Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening: Reducing the Risk of Drug-Induced QT Interval Lengthening in Women
J
James Tisdale
Primary Investigator
Not Recruiting
21 years - 100 years
Female
Phase
N/A
1 Location
Brief description of study
The purpose of this study is to determine the effectiveness of progesterone given by mouth for minimizing drug EKG response to a drug.
Detailed description of study
Our objective is to evaluate and compare the efficacy of novel therapeutic approaches to reduce the risk of drug-induced QTc interval prolongation and TdP.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Torsades de pointes,menopause,healthy,Torsades de pointe
-
Age: 21 years - 100 years
-
Gender: Female
Inclusion Criteria
Postmenopausal women, based on the following criteria:
Age 50 years of age or older AND
Postmenopausal women, based on the following criteria:
Age 50 years of age or older AND
No menstrual periods for 365 days or longer
Premenopausal women:
21-40 years of age
Exclusion Criteria
History of breast, ovarian or uterine cancer
Taking hormone replacement therapy
Heart failure due to reduced ejection fraction (left ventricular ejection fraction 40%)
Family or personal history of long-QT syndrome, arrhythmias or sudden cardiac death
Concomitant use of any QT interval prolonging drug
Permanently paced ventricular rhythm
Additional Information:History of breast, ovarian or uterine cancer
Taking hormone replacement therapy
Heart failure due to reduced ejection fraction (left ventricular ejection fraction 40%)
Family or personal history of long-QT syndrome, arrhythmias or sudden cardiac death
Concomitant use of any QT interval prolonging drug
Permanently paced ventricular rhythm
Participants will be paid for their participation.
Updated on
01 Aug 2024.
Study ID: 1806935117
